By otakuyassine3@gmail.com 
Raymond James Financial Inc. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 456,774 shares of the biopharmaceutical company’s stock, valued at approximately $21,838,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $69,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter worth about $1,886,000. Segall Bryant & Hamill LLC lifted its stake in shares of Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after purchasing an additional 49,856 shares in the last quarter. Retirement Systems of Alabama lifted its stake in shares of Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares in the last quarter. Finally, South Street Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter worth about $9,812,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on HALO. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Benchmark restated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $62.78.
Read Our Latest Research Report on Halozyme Therapeutics
Insider Activity at Halozyme Therapeutics
In related news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 over the last three months. 2.40% of the stock is owned by insiders.
Halozyme Therapeutics Stock Up 2.0 %
Shares of Halozyme Therapeutics stock opened at $62.27 on Friday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm has a market cap of $7.67 billion, a P/E ratio of 18.15, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The business has a 50-day moving average price of $57.05 and a 200 day moving average price of $54.70.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Stories
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Halozyme Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.